









Markets
/
Stocks
/
nasdaq-evax
/

Evaxion Biotech A/S

EVAX

6.000USD

-0.380-5.96%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.89BMarket Cap

LossP/E TTM



Evaxion Biotech A/S

6.000

-0.380-5.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Evaxion Biotech A/S

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evaxion Biotech A/S's Score

Industry at a Glance

Industry Ranking

176 / 407

Overall Ranking

313 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+93.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evaxion Biotech A/S Highlights

StrengthsRisks

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.34M.

Overvalued

The company’s latest PE is -0.25, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 119.22K shares, decreasing 42.85% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 7.14, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 37.00K, representing a year-over-year decrease of 75.97%, while its net profit experienced a year-over-year decrease of 22.06%.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.87

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.91

Key Metrics

Free cash flow

No Data

Evaxion Biotech A/S's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.49, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.25, which is -51.10% below the recent high of -0.12 and -8526.97% above the recent low of -21.59.

Score

Industry at a Glance

Previous score

6.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 176/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Evaxion Biotech A/S is 11.00, with a high of 16.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+93.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Evaxion A/S

EVAX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 5.27, which is lower than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 10.59 and the support level at 3.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.91

Change

-0.64

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.193

Neutral

RSI(14)

50.844

Neutral

STOCH(KDJ)(9,3,3)

54.712

Neutral

ATR(14)

0.599

Low Volatility

CCI(14)

39.792

Neutral

Williams %R

57.746

Sell

TRIX(12,20)

0.180

Sell

StochRSI(14)

35.067

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

6.136

Sell

MA10

5.931

Buy

MA20

6.494

Sell

MA50

5.057

Buy

MA100

3.899

Buy

MA200

2.977

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 1.50%, representing a quarter-over-quarter decrease of 94.03%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Merck & Co Inc

1.21M

Merck Sharp & Dohme Corporation

242.82K

+123.89%

Ikarian Capital LLC

80.00K

Boothbay Fund Management, LLC

23.73K

Rhumbline Advisers Ltd. Partnership

9.44K

+327.01%

GAMMA Investing LLC

3.31K

-5.27%

UBS Financial Services, Inc.

2.04K

-68.71%

Geode Capital Management, L.L.C.

621.00

SBI Securities Co., Ltd.

64.00

-97.40%

Osaic Holdings, Inc.

25.00

Risk Assessment

Currency: USD Updated: 2025-11-10

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.